Source: Eur Respir J 2009; 34: 1204-1206



Rating:

Share or cite this content

Citations should be made in the following way:
Montani D., Jais X., Dorfmuller P., Simonneau G., Sitbon O., Humbert M.. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J 2009; 34: 1204-1206

Member's Comments

No comment yet.

Related content which might interest you: Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease Source: Eur Respir J 2009; 34: 1348-1356 Year: 2009 An autopsy case of pulmonary veno-occlusive disease refractory to imatinib Source: Eur Respir J 2011; 37: 968-970 Year: 2011 Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures Source: Eur Respir J 2005; 26: 755-758 Year: 2005 Challenging cases in PH Source: Eur Respir Rev 2008; 17: 19-23 Year: 2007 The use of genetic testing in an atypical presentation of pulmonary veno-occlusive disease Source: Virtual Congress 2020 – Pulmonary vascular diseases Year: 2020 Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014 Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension Source: Eur Respir Rev 2009; 18: 177-180 Year: 2009 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Pulmonary veno-occlusive disease Source: Eur Respir J 2016; 47:1518-1534 Year: 2016 Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution Source: Eur Respir J, 55 (6) 1902418; 10.1183/13993003.02418-2019 Year: 2020 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment Source: Eur Respir J 2014; 43: 1516-1519 Year: 2014 Microvascular disease in chronic thromboembolic pulmonary hypertension: the story continues Source: Eur Respir J 2014; 44: 1121-1122 Year: 2014 Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach Source: Eur Respir J 2015; 45: 1142-1149 Year: 2015 Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation Source: Eur Respir Rev 2014; 23: 488-497 Year: 2014